California-based biopharma company Alumis is making a significant push towards the oral psoriasis market with its investigational drug, envudeucitinib. Recent Phase III data from the ONWARD program suggests the tyrosine kinase 2 (TYK2) inhibitor possesses leading potential, showcasing durable efficacy and robust patient-reported outcomes. However, the company faces an increasingly crowded and competitive landscape, with established players and new entrants vying for market share.
Alumis has unveiled compelling data from a trio of pivotal Phase III studies, the ONWARD program (NCT06586112; NCT06588738; NCT06846541). These trials, designed to evaluate envudeucitinib’s efficacy and safety in patients with moderate to severe plaque psoriasis, have provided robust evidence of the drug’s potential to offer a significant therapeutic advancement. The company is now on track to submit a New Drug Application (NDA) to regulatory authorities in the fourth quarter of 2026, signaling a determined stride towards market approval.
The ONWARD program’s design included two randomized controlled trials, ONWARD 1 and ONWARD 2, which directly compared envudeucitinib against Amgen’s existing oral psoriasis treatment, Otezla (apremilast), and a placebo. A third, open-label study, ONWARD 3, was designed to assess the long-term efficacy and safety profile of envudeucitinib in patients who transitioned from the initial two trials. This comprehensive approach aims to provide a thorough understanding of envudeucitinib’s performance and tolerability across a diverse patient population.
A Deep Dive into the ONWARD Program: Demonstrating Durable Efficacy and Patient-Centric Benefits
The published data from the ONWARD program highlights several key areas of improvement for patients treated with envudeucitinib. Building upon earlier promising results, the latest findings indicate that 54% of patients receiving twice-daily envudeucitinib achieved a complete response, as measured by the Psoriasis Area and Severity Index (PASI) scale, at the 48-week mark. This sustained efficacy suggests a long-term impact on the disease burden for a significant proportion of patients.
Furthermore, the ONWARD 3 study demonstrated a remarkable durability of effect, with 80% of patients maintaining a clear or almost clear scalp – a crucial area of concern for many psoriasis sufferers – at 48 weeks of treatment. This sustained control over a significant symptom of psoriasis underscores the potential of envudeucitinib to offer lasting relief.
Beyond the objective measures of skin clearance, the ONWARD studies also captured the profound impact of envudeucitinib on patient-reported outcomes, particularly concerning pruritus, or itch. One in three patients treated with envudeucitinib experienced a clinically meaningful reduction in itch within the ONWARD 1 and 2 studies. Encouragingly, this relief was observed as early as week two, suggesting a rapid onset of action for this debilitating symptom. The long-term benefits were also evident, with 80% of patients in the open-label study maintaining their itch reduction up to 48 weeks. This sustained relief from itching can significantly improve a patient’s daily comfort and overall well-being.
The drug’s positive influence extended to patients’ quality of life (QoL). At week 12, half of the patients treated with envudeucitinib reported that their psoriasis had minimal to no impact on their daily lives. This positive trajectory continued, with over 70% of patients maintaining this improved QoL after 48 weeks of treatment in the ONWARD 3 study. This indicates that envudeucitinib not only addresses the physical manifestations of psoriasis but also significantly enhances patients’ ability to engage in daily activities and experience a better overall life.
Crucially, the safety profile of envudeucitinib in the ONWARD program appears favorable. Researchers reported that patients tolerated the drug well, and importantly, no new safety signals were identified in conjunction with long-term treatment. This is a critical factor for chronic conditions like psoriasis, where patients often require extended therapy. The absence of novel safety concerns further bolsters the potential for envudeucitinib to become a viable long-term treatment option.
Navigating a Crowded Battlefield: Understanding the Competitive Landscape
While Alumis celebrates these positive clinical milestones, the path to market approval and subsequent commercial success for envudeucitinib is fraught with significant challenges. The oral psoriasis market is a highly competitive arena, populated by established and emerging therapies that offer varying mechanisms of action and patient benefits.
If envudeucitinib gains regulatory approval, it will enter a market already featuring potent players. Among these are Johnson & Johnson’s (J&J) newly approved psoriasis pill, Icotyde (icotrokinra). Analysts have lauded Icotyde for achieving "biologic-like efficacy in a once-daily oral pill," a proposition that offers a more convenient dosing schedule than envudeucitinib’s twice-daily requirement. The convenience factor is a significant differentiator in patient preference and adherence, potentially posing a substantial hurdle for envudeucitinib.
Another formidable competitor is Amgen’s Otezla (apremilast), which has served as a benchmark in the oral psoriasis treatment landscape and was included as a comparator in the ONWARD trials. While envudeucitinib demonstrated superiority over placebo and potentially Otezla in the ONWARD studies, Otezla has a well-established track record and patient base.
Bristol Myers Squibb’s (BMS) Sotyktu (deucravacitinib) is also a key player. As a fellow TYK2 inhibitor, Sotyktu represents a direct competitor with a similar mechanism of action. Sotyktu generated $291 million in sales last year, indicating its strong market presence. Alumis aims to differentiate envudeucitinib by highlighting its engineered mechanism designed to engage and inhibit TYK2 over a continuous 24-hour period, potentially offering a more sustained therapeutic effect compared to Sotyktu’s dosing regimen.
Adding to the competitive pressure is Takeda’s investigational psoriasis drug, zasocitinib. While still in development, zasocitinib has shown promising results in Phase III trials, and its efficacy data, alongside that of Icotyde, has led some analysts, such as those at Jefferies, to suggest that envudeucitinib’s efficacy might fall short of these emerging therapies. This comparative analysis of efficacy could potentially limit envudeucitinib’s differentiation and market penetration.
The existence of these established and emerging treatments means that Alumis will need to present a compelling value proposition to healthcare providers and patients. Factors such as clinical efficacy, safety profile, dosing convenience, and ultimately, price, will play crucial roles in determining envudeucitinib’s market success.
The Road Ahead: Regulatory Submissions and Market Entry
Alumis’s strategic decision to pursue an NDA submission for envudeucitinib in plaque psoriasis in Q4 2026 indicates a confident outlook based on the robust Phase III data. The company’s focus on demonstrating leading potential, particularly in terms of durable efficacy and significant improvements in patient-reported outcomes like itch and quality of life, is a sound strategy in a market where patient experience is increasingly valued.
The company’s efforts to position envudeucitinib as a superior option, particularly in its mechanism of action designed for 24-hour TYK2 inhibition, will be crucial in differentiating it from other TYK2 inhibitors like Sotyktu. However, the convenience offered by once-daily oral medications like Icotyde presents a significant challenge that Alumis will need to address through its marketing and physician education efforts.
The forthcoming regulatory review process will be a critical juncture for Alumis. The company will need to present a comprehensive and convincing data package that addresses all potential concerns from regulatory bodies. If approved, the subsequent market launch will require a carefully crafted commercial strategy to effectively compete against the well-entrenched players in the oral psoriasis market.
The success of envudeucitinib will hinge not only on its clinical profile but also on Alumis’s ability to navigate the complex pricing and reimbursement landscape, and to effectively communicate its unique benefits to both healthcare professionals and patients. The coming years will be pivotal for Alumis as it strives to carve out a significant niche for envudeucitinib in the evolving and dynamic psoriasis treatment market. The company’s investment in extensive Phase III trials suggests a strong commitment to bringing this potential new therapy to patients, but the competitive headwinds are undeniable.
About the Author
